05:51 AM EDT, 08/14/2025 (MT Newswires) -- Sarepta Therapeutics ( SRPT ) said late Wednesday it has sold about 9.3 million common shares of Arrowhead Pharmaceuticals ( ARWR ) for at least $174 million in gross proceeds.

The company also entered into an agreement with Arrowhead, wherein it will transfer about 2.7 million in Arrowhead shares in satisfaction of the $50 million of its previously announced $100 million milestone payment obligation.

Sarepta Therapeutics ( SRPT ) said the $100 million milestone payment obligation was triggered following a review of the safety data and Arrowhead achieving the first of two predetermined enrollment targets, in the phase 1/2 clinical study of SRP-1003, an investigational RNA interference therapeutic for the treatment of type 1 myotonic dystrophy.

Sarepta Therapeutics ( SRPT ) shares were up 4.7% in recent premarket activity.